Allogeneic natural killer cell line NK-92

Drug Overview

The medication known as NK-92 is a pioneering cellular immunotherapy that serves as a foundation for modern “off-the-shelf” cancer treatments. Unlike traditional therapies that rely on a patient’s own immune cells, which can be weakened by disease or chemotherapy, NK-92 uses a standardized, highly aggressive line of Natural Killer (NK) cells. These cells are grown in specialized laboratories, allowing doctors to provide a consistent and potent treatment to patients immediately, without the weeks of waiting required for personalized cell manufacturing.

In clinical terms, NK-92 is an Allogeneic Natural Killer Cell Line. Derived originally from a patient with a rare form of lymphoma, these cells have been “immortalized” and optimized to act as professional cancer hunters. Because they are “allogeneic” (meaning they come from a different source than the patient), they can be mass-produced and frozen for global distribution.

Here are the key details about this agent:

• Generic Name: Allogeneic natural killer cell line NK-92.
• US Brand Names: None yet (Investigational variants are often called haNK or t-haNK).
• Drug Class: Immunotherapy / Adoptive Cell Therapy / NK Cell Line.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. It is currently being evaluated in Phase I and Phase II clinical trials for both blood cancers and solid tumors.

What Is It and How Does It Work? (Mechanism of Action)

NK-92 is a “Smart Drug” designed to bypass the tricks cancer cells use to hide. To understand its power, we must look at the molecular signals that allow it to identify and destroy tumors.

The Missing “ID Badge” (Missing-Self Recognition)

Most healthy cells in the human body carry a protein called MHC Class I, which acts like an ID badge. When cancer cells develop, they often hide this badge so that T-cells (the body’s other immune soldiers) cannot see them. However, NK-92 cells are programmed specifically to attack cells that are missing this “ID badge.” This makes them exceptionally good at finding drug-resistant cancers that other treatments miss.

Molecular Level Mechanisms

1. Receptor Activation: NK-92 cells express high levels of activating receptors, such as NKG2D and NKp46. These act as molecular sensors that detect “stress signals” on the surface of cancer cells.
2. Lacks Inhibitory Signals: Naturally occurring NK cells in our bodies have “brakes” called Killer Immunoglobulin-like Receptors (KIRs). Cancer cells often pull these brakes to stop an attack. Remarkably, the NK-92 cell line is naturally devoid of KIRs. This means the “brakes” are removed, allowing the cells to stay in a permanent “attack mode” against tumors.
3. Lytic Granule Release: Once NK-92 attaches to a tumor, it releases chemical “bombs” called perforin and granzyme B. Perforin creates holes in the cancer cell’s wall, while granzymes enter and trigger a programmed self-destruction (apoptosis).
4. ADCC Enhancement: Modern versions of NK-92 (like haNK) are engineered to express the CD16 receptor. This allows the cells to “grab onto” other cancer-targeting antibodies (like Trastuzumab or Rituximab), significantly increasing the effectiveness of those combined treatments.

FDA-Approved Clinical Indications

As an investigational therapy, NK-92 does not yet have official FDA approval for general use. However, it is a primary focus in clinical trials for the following conditions:

Oncological Uses (In Clinical Trials):

• Acute Myeloid Leukemia (AML): Used to kill remaining leukemia cells that chemotherapy cannot reach.
• Multiple Myeloma: Testing its ability to target plasma cell cancers in the bone marrow.
• Non-Hodgkin Lymphoma: Evaluated as a potential treatment for aggressive blood cancers.
• Solid Tumors (Lung, Breast, and Renal Cell Carcinoma): Specifically being tested in patients whose tumors have stopped responding to standard “checkpoint inhibitor” drugs.

Non-oncological Uses:

• Antiviral Research: Early-stage research is investigating if NK-92 can be used to treat severe viral infections that hide from the immune system, though this is not yet a standard clinical use.

Dosage and Administration Protocols

NK-92 is administered as a live cell infusion. Because these cells are a “cell line,” they are irradiated (treated with a small dose of radiation) before infusion. This ensures they can kill cancer for a few days but cannot grow or multiply inside the patient’s body, providing an extra layer of safety.

Clinical Efficacy and Research Results

Clinical data from 2020 to 2025 have highlighted NK-92’s potential as a safe and effective “bridge” to other therapies.

• Safety Profile Results: In a Phase I trial involving patients with relapsed blood cancers, NK-92 was shown to be safe even at high doses (up to 5 billion cells). Over 75% of patients in certain small cohorts tolerated the infusions without any severe immune reactions.
• Disease Progression: For patients with advanced lung cancer (NSCLC), combination trials using NK-92 alongside PD-L1 inhibitors showed a Disease Control Rate (DCR) of nearly 80% in early pilot studies.
• Survival Data: While long-term survival rates are still being tracked, median Progression-Free Survival (PFS) in aggressive lymphoma patients receiving NK-92 as a “salvage” therapy showed an improvement of several months compared to those on standard supportive care.

Safety Profile and Side Effects

NK-92 is generally better tolerated than T-cell therapies (like CAR-T) because it is less likely to cause the “immune storms” that require intensive care.

Common Side Effects (>10%):

• Infusion-Related Fever: A mild fever that usually happens within hours of the treatment.
• Chills and Shaking: Often managed with simple warming blankets or medication.
• Mild Nausea: Occasional stomach upset during the infusion process.
• Fatigue: A feeling of tiredness that typically resolves within 48 hours.

Serious Adverse Events:

• Hypersensitivity: Rare allergic reactions to the cell-storage solution.
• Transient Blurred Vision: Reported in a very small number of cases, usually resolving within 6 hours.
• Black Box Warning: There is currently no FDA Black Box Warning for NK-92.
• Management Strategies: Patients are “pre-medicated” with acetaminophen (Tylenol) and diphenhydramine (Benadryl) to prevent fevers. To manage the cell’s short lifespan in the body, clinicians may also provide low-dose Interleukin-2 (IL-2) injections to keep the NK-92 cells active for a longer period.

Research Areas

NK-92 has a significant connection to Regenerative Medicine and Stem Cell Therapy. In the setting of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), NK cells are often the first part of the immune system to recover. Researchers are currently using NK-92 as a “supplement” after a stem cell transplant. The goal is to use these donor cells to provide immediate protection against infection and “graft-versus-leukemia” effects while the patient’s new stem cells are still maturing. This regenerative approach helps the body rebuild a healthy immune system while keeping the cancer away.

Patient Management and Practical Recommendations

Success with NK-92 requires careful preparation and follow-up.

Pre-treatment Tests to be Performed:

• Blood Chemistry: Comprehensive panels to check kidney and liver health.
• Infectious Disease Screening: Mandatory testing for HIV, Hepatitis B, and Hepatitis C.
• Pregnancy Test: Required for women of childbearing age within 7 days of the first infusion.
• Tumor Imaging: A baseline CT or PET scan to track the size of the tumor before starting.

Precautions During Treatment:

• Radiation Safety: Although the cells are irradiated to stop their growth, this does not make the patient radioactive.
• Steroid Avoidance: Patients should avoid high-dose steroids right before treatment, as these can weaken the NK-92 cells.

“Do’s and Don’ts” List:

• DO report any fever higher than 100.4°F (38°C) to your care team immediately.
• DO drink plenty of fluids to help your kidneys process the cellular byproducts.
• DON’T miss your scheduled blood draws, as monitoring your cell counts is vital for safety.
• DON’T drive yourself home after the first infusion, in case you feel tired or dizzy.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. NK-92 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.